Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011003885 - METHOD FOR PREDICTING DISEASE FREE SURVIVAL IN PATIENTS WITH OVARIAN CANCER

Publication Number WO/2011/003885
Publication Date 13.01.2011
International Application No. PCT/EP2010/059598
International Filing Date 06.07.2010
IPC
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
CPC
G01N 2333/4728
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
46from vertebrates
47Assays involving proteins of known structure or function as defined in the subgroups
4701Details
4728alpha-Glycoproteins
G01N 2800/54
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
54Determining the risk of relapse
G01N 33/57449
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
57407Specifically defined cancers
57449of ovaries
Applicants
  • STICHTING KATHOLIEKE UNIVERSITEIT [NL]/[NL] (AllExceptUS)
  • MASSUGER, Leonardus Franciscus Adrianus Gerardus [NL]/[NL] (UsOnly)
  • WEVERS, Ronald Allan [NL]/[NL] (UsOnly)
Inventors
  • MASSUGER, Leonardus Franciscus Adrianus Gerardus
  • WEVERS, Ronald Allan
Agents
  • HABETS, Winand Johannes Antonius
Priority Data
09164615.806.07.2009EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHOD FOR PREDICTING DISEASE FREE SURVIVAL IN PATIENTS WITH OVARIAN CANCER
(FR) PROCÉDÉ DESTINÉ À PRÉDIRE LA SURVIE SANS RÉCIDIVE CHEZ DES PATIENTS ATTEINTS DU CANCER DE L'OVAIRE
Abstract
(EN)
The invention is in the field of molecular medicine and provides methods for predicting the outcome of chemotherapy in ovarian cancer. It also provides methods for the screening of test compounds that may improve the efficacy of a chemotherapeutic agent in the chemotherapy of ovarian cancer. The invention provides an in vitro method for predicting the outcome of chemotherapy in ovarian cancer comprising the steps of providing a test sample comprising ovarian cyst fluid, determining the level of alpha-1 acid glycoprotein in the test sample and comparing the level of alpha-1 acid glycoprotein in the test sample with a control level of alpha-1 acid glycoprotein wherein a level of alpha-1 acid glycoprotein in the test sample higher than a control level of alpha-1 acid glycoprotein indicates that the individual is at an increased risk for recurrent disease.
(FR)
La présente invention appartient au domaine de la médecine moléculaire et concerne des procédés destinés à prédire l'issue d'une chimiothérapie d'un cancer de l'ovaire. L'invention concerne également des procédés de criblage de composés tests qui peuvent améliorer l'efficacité d'un agent chimiothérapique en chimiothérapie d'un cancer de l'ovaire. L'invention concerne en outre un procédé in vitro destiné à prédire l'issue d'une chimiothérapie d'un cancer de l'ovaire comprenant les étapes consistant à fournir un échantillon test comprenant un fluide de kyste ovarien, à déterminer le taux d'alpha-1 glycoprotéine acide dans l'échantillon test et à comparer le taux d'alpha-1 glycoprotéine acide dans l'échantillon test avec un taux de contrôle de l'alpha-1 glycoprotéine acide, un taux d'alpha-1 glycoprotéine acide dans l'échantillon test plus élevé qu'un taux de contrôle de l'alpha-1 glycoprotéine acide indiquant que l'individu a un risque élevé de souffrir de manière plus récurrente de sa maladie.
Latest bibliographic data on file with the International Bureau